Innovative Medical Treatments for Endometriosis Highlighted at SEUD Congress in Prague

The recent SEUD Congress, held in Prague from April 24 to 26, 2025, brought together leading experts to discuss the latest advancements in medical treatment options for endometriosis. Supported by Gedeon Richter, this symposium attracted hundreds of participants keen to explore the progressive approaches aimed at managing this chronic condition affecting over 190 million women worldwide.

Endometriosis is a painful disorder characterized by the growth of tissue similar to the lining inside the uterus, which occurs outside the uterus itself. This abnormal growth leads to inflammation, scarring, and significant pain, thereby affecting women’s fertility and overall quality of life. Alarmingly, many women suffer for an extended period, often 7 to 9 years, before receiving a correct diagnosis and treatment.

Traditionally, surgical intervention was the primary strategy for managing endometriosis; however, there is a shift towards non-invasive medical therapies that boast sustainable and effective long-term results. Hormonal treatments are now gaining favor for their ability to reduce estrogen levels, which correlates with the slowdown of endometrial-like tissue growth. Research indicates that over 70% of women undergoing hormone therapy experience considerable relief from pain and improvement in their quality of life.

One groundbreaking treatment available on the market combines GnRH receptor antagonists, designed specifically for symptomatic endometriosis and uterine fibroids. This medication, which can be taken orally once a day, provides a comprehensive approach to managing the disease by targeting various underlying mechanisms and delivering rapid, lasting symptom relief. Its safety profile and convenience offer women a viable alternative to surgery.

Péter Turek, head of Gedeon Richter's Women's Healthcare unit, expressed that as a prominent player in the pharmaceutical sector focusing on women’s health, their aim is to offer innovative solutions that enhance women's lives. He stated, "We believe that the continuous development of treatment options like our endometriosis medication is crucial in improving the quality of life for millions of women globally."

While surgical options remain a necessary recourse for severe cases, they come with inherent risks, including a 30-50% chance of symptom recurrence within five years. In contrast, modern pharmacological treatments provide a safer, long-term approach that helps women maintain their health, fertility, and overall quality of life.

The advancements presented at the SEUD Congress signify a shift towards innovative therapies that promise hope for millions of women living with endometriosis. Non-invasive solutions can now effectively control symptoms, allowing women to reclaim their lives and alleviate the burden of pain.

In summary, the SEUD Congress highlighted the pressing need for modern medical approaches in the fight against endometriosis, affirming Gedeon Richter's commitment to advancing women's health through progressive treatment options that prioritize patient-centered care and personalized solutions.